Expand All | Collapse All
- A - Alimentary tract and metabolism
- A01 - Stomatological preparations
- A01A - Stomatological preparations
- A01AA - Caries prophylactic agents
- A02 - Drugs for acid related disorders
- A02B - Drugs for treatment of peptic ulcer
- A02BC - Proton pump inhibitors
- A02BC01 - Omeprazole
- A02BC02 - Pantoprazole
- A02BC03 - Lansoprazole
- A03 - Drugs for functional gastrointestinal disorders
- A03A - Drugs for functional bowel disorders
- A03AE - Drugs acting on serotonin receptors
- A03AE02 - Tegaserod
- A03AE04 - Prucalopride
- A03F - Propulsives
- A03FA - Propulsives
- A03FA02 - Cisapride
- A03FA03 - Domperidone
- A04 - Antiemetics and antinauseants
- A04A - Antiemetics and antinauseants
- A04AA - Serotonin (5HT3) antagonists
- A04AA02 - Granisetron
- A04AA05 - Palonosetron
- A04AD - Other antiemetics
- A05 - Bile and liver therapy
- A05A - Bile therapy
- A05AA - Bile acid preparations
- A06 - Laxatives
- A06A - Laxatives
- A06AH - Peripheral opioid receptor antagonists
- A06AH01 - Methylnaltrexone bromide
- A08 - Antiobesity preparations, excluding diet products
- A08A - Antiobesity preparations, excluding diet products
- A08AA - Centrally acting antiobesity products
- A08AA01 - Phentermine
- A08AA02 - Fenfluramine
- A08AA03 - Amfepramone
- A08AA04 - Dexfenfluramine
- A08AA05 - Mazindol
- A08AA08 - Clobenzorex
- A08AA09 - Mefenorex
- A08AA10 - Sibutramine
- A08AB - Peripherally acting antiobesity products
- A08AX - Other antiobesity drugs
- A10 - Drugs used in diabetes
- A10A - Insulins and analogues
- A10AB - Insulins and analogues for injection, fast-acting
- A10AB01 - Insulin (human)
- A10AB04 - Insulin lispro
- A10AB05 - Insulin aspart
- A10AB06 - Insulin glulisine
- A10AC - Insulins and analogues for injection, intermediate-acting
- A10AC01 - Insulin (human)
- A10AD - Insulins and analogues for injection, intermediate-acting combined with fast-acting
- A10AD01 - Insulin (human)
- A10AD05 - Insulin aspart
- A10AE - Insulins and analogues for injection, long-acting
- A10AE04 - Insulin glargine
- A10AE05 - Insulin detemir
- A10AF - Insulins and analogues, for inhalation
- A10AF01 - Insulin (human)
- A10B - Blood glucose lowering drugs, excluding insulins
- A10BA - Biguanides
- A10BB - Sulfonamides, urea derivatives
- A10BD - Combinations of oral blood glucose lowering drugs
- A10BD03 - Metformin and rosiglitazone
- A10BD04 - Glimepiride and rosiglitazone
- A10BD05 - Metformin and pioglitazone
- A10BD06 - Glimepiride and pioglitazone
- A10BD07 - Metformin and sitagliptin
- A10BD08 - Metformin and vildagliptin
- A10BG - Thiazolidinediones
- A10BG02 - Rosiglitazone
- A10BG03 - Pioglitazone
- A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
- A10BH01 - Sitagliptin
- A10BH02 - Vildagliptin
- A10BH03 - Saxagliptin
- A10BH05 - Linagliptin
- A10BX - Other oral blood glucose lowering drugs
- A10BX02 - Repaglinide
- A10BX03 - Nateglinide
- A10BX04 - Exenatide
- A10BX06 - Benfluorex
- A10BX07 - Liraglutide
- A11 - Vitamins
- A11H - Other plain vitamin preparations
- A11HA - Other plain vitamin preparations
- A16 - Other alimentary tract and metabolism products
- A16A - Other alimentary tract and metabolism products
- A16AA - Amino acids and derivatives
- A16AA04 - Mercaptamine
- A16AA05 - Carglumic acid
- A16AA06 - Betaine
- A16AB - Enzymes
- A16AB02 - Imiglucerase
- A16AB03 - Agalsidase alfa
- A16AB04 - Agalsidase beta
- A16AB05 - Laronidase
- A16AB07 - Alglucosidase alfa
- A16AB08 - Galsulfase
- A16AB09 - Idursulfase
- A16AB10 - Velaglucerase alfa
- A16AX - Various alimentary tract and metabolism products
- A16AX03 - Sodium phenylbutyrate
- A16AX04 - Nitisinone
- A16AX05 - Zinc acetate
- A16AX06 - Miglustat
- A16AX07 - Sapropterin
- B - Blood and blood forming organs
- B01 - Antithrombotic agents
- B01A - Antithrombotic agents
- B01AB - Heparin group
- B01AC - Platelet aggregation inhibitors excluding Heparin
- B01AC04 - Clopidogrel
- B01AC11 - Iloprost
- B01AC16 - Eptifibatide
- B01AC17 - Tirofiban
- B01AC22 - Prasugrel
- B01AC24 - Ticagrelor
- B01AC30 - Combinations
- B01AD - Enzymes
- B01AD02 - Alteplase
- B01AD07 - Reteplase
- B01AD08 - Saruplase
- B01AD10 - Drotrecogin alfa (activated)
- B01AD11 - Tenecteplase
- B01AD12 - Protein C
- B01AE - Direct thrombin inhibitors
- B01AE01 - Desirudin
- B01AE02 - Lepirudin
- B01AE06 - Bivalirudin
- B01AE07 - Dabigatran etexilate
- B01AX - Other antithrombotic agents
- B01AX05 - Fondaparinux
- B01AX06 - Rivaroxaban
- B02 - Antihemorrhagics
- B02A - Antifibrinolytics
- B02AA - Amino acids
- B02AA02 - Tranexamic acid
- B02AB - Proteinase inhibitors
- B02B - Vitamin K and other hemostatics
- B02BC - Local hemostatics
- B02BD - Blood coagulation factors
- B02BD02 - Coagulation factor VIII
- B02BD04 - Coagulation factor IX
- B02BD05 - Coagulation factor VII
- B02BX - Other systemic hemostatics
- B02BX04 - Romiplostim
- B02BX05 - Eltrombopag
- B03 - Antianemic preparations
- B03X - Other antianemic preparations
- B03XA - Other antianemic preparations
- B03XA01 - Erythropoietin
- B03XA02 - Darbepoetin alfa
- B03XA03 - Methoxy polyethylene glycol-epoetin beta
- B06 - Other hematological agents
- B06A - Other hematological agents
- B06AC - Drugs used in hereditary angioedema
- B06AC01 - C1-inhibitor, plasma derived
- C - Cardiovascular system
- C01 - Cardiac therapy
- C01B - Antiarrhythmics, class I and III
- C01BD - Antiarrhythmics, class III
- C01BD04 - Dofetilide
- C01BD07 - Dronedarone
- C01E - Other cardiac preparations
- C01EB - Other cardiac preparations
- C01EB16 - Ibuprofen
- C01EB17 - Ivabradine
- C01EB18 - Ranolazine
- C01EB19 - Icatibant
- C01EB21 - Regadenoson
- C02 - Antihypertensives
- C02C - Antiadrenergic agents, peripherally acting
- C02CA - Alpha-adrenoceptor blocking agents
- C02K - Other antihypertensives
- C02KX - Other antihypertensives
- C02KX01 - Bosentan
- C02KX02 - Ambrisentan
- C02KX03 - Sitaxentan
- C03 - Diuretics
- C03X - Other diuretics
- C03XA - Vasopressin antagonists
- C04 - Peripheral vasodilators
- C04A - Peripheral vasodilators
- C04AX - Other peripheral vasodilators
- C07 - Beta blocking agents
- C07A - Beta blocking agents, plain
- C07AB - Beta blocking agents, plain, selective
- C07AB52 - Metoprolol, combinations
- C08 - Calcium channel blockers
- C08C - Selective calcium channel blockers with mainly vascular effects
- C08CA - Dihydropyridine derivatives
- C08CA01 - Amlodipine
- C08CA02 - Felodipine
- C08CA05 - Nifedipine
- C09 - Agents acting on the renin-angiotensin system
- C09A - ACE inhibitors, plain
- C09AA - ACE inhibitors, plain
- C09AA01 - Captopril
- C09AA02 - Enalapril
- C09AA03 - Lisinopril
- C09AA04 - Perindopril
- C09AA05 - Ramipril
- C09AA08 - Cilazapril
- C09AA15 - Zofenopril
- C09B - ACE inhibitors, combinations
- C09BA - ACE inhibitors and diuretics
- C09BA08 - Cilazapril and diuretics
- C09BB - ACE inhibitors and calcium channel blockers
- C09BB03 - Lisinopril and amlodipine
- C09C - Angiotensin II antagonists, plain
- C09CA - Angiotensin II antagonists, plain
- C09CA01 - Losartan
- C09CA03 - Valsartan
- C09CA04 - Irbesartan
- C09CA07 - Telmisartan
- C09CA09 - Azilsartan medoxomil
- C09D - Angiotensin II antagonists, combinations
- C09DA - Angiotensin II antagonists and diuretics
- C09DA04 - Irbesartan and diuretics
- C09DA06 - Candesartan and diuretics
- C09DA07 - Telmisartan and diuretics
- C09DB - Angiotensin II antagonists and calcium channel blockers
- C09DB01 - Valsartan and amlodipine
- C09DB04 - Telmisartan and amlodipine
- C09DX - Angiotensin II antagonists, other combinations
- C09DX01 - Valsartan, amlodipine and hydrochlorothiazide
- C09X - Other agents acting on the renin-angiotensin system
- C09XA - Renin-inhibitors
- C09XA02 - Aliskiren
- C09XA52 - Aliskiren and hydrochlorothiazide
- C09XA53 - Aliskiren and amlodipine
- C09XA54 - Aliskiren, amlodipine and hydrochlorothiazide
- C10 - Lipid modifying agents
- C10A - Lipid modifying agents, plain
- C10AA - Hmg coa reductase inhibitors
- C10AA01 - Simvastatin
- C10AA03 - Pravastatin
- C10AA04 - Fluvastatin
- C10AA05 - Atorvastatin
- C10AA06 - Cerivastatin
- C10AA07 - Rosuvastatin
- C10AB - Fibrates
- C10AC - Bile acid sequestrants
- C10AD - Nicotinic acid and derivatives
- C10AD52 - Nicotinic acid, combinations
- C10AX - Other lipid modifying agents
- C10B - Lipid modifying agents, combinations
- C10BA - HMG CoA reductase inhibitors in combination with other lipid modifying agents
- C10BA03 - Pravastatin and fenofibrate
- D - Dermatologicals
- D01 - Antifungals for dermatological use
- D01A - Antifungals for topical use
- D01AC - Imidazole derivatives
- D03 - Preparations for treatment of wounds & ulcers
- D03A - Cicatrizants
- D03AX - Other cicatrizants
- D05 - Antipsoriatics
- D05A - Antipsoriatics for topical use
- D05AX - Other antipsoriatics for topical use
- D05AX52 - Calcipotriol, combinations
- D06 - Antibiotics and chemotherapeutics for dermatological use
- D06A - Antibiotics for topical use
- D06AX - Other antibiotics for topical use
- D06B - Chemotherapeutics for topical use
- D10 - Anti-acne preparations
- D10A - Anti-acne preparations for topical use
- D10AD - Retinoids for topical use in acne
- D11 - Other dermatological preparations
- D11A - Other dermatological preparations
- D11AH - Agents for atopic dermatitis, excluding corticosteroids
- D11AH01 - Tacrolimus
- D11AH02 - Pimecrolimus
- D11AX - Other dermatologicals
- G - Genito urinary system and sex hormones
- G02 - Other gynecologicals
- G02C - Other gynecologicals
- G02CB - Prolactine inhibitors
- G02CX - Other gynecologicals
- G03 - Sex hormones and modulators of the genital system
- G03A - Hormonal contraceptives for systemic use
- G03AA - Progestogens and estrogens, fixed combinations
- G03AA14 - Nomegestrol and estrogen
- G03AC - Progestogens
- G03B - Androgens
- G03BA - 3-oxoandrosten (4) derivatives
- G03G - Gonadotropins and other ovulation stimulants
- G03GA - Gonadotropins
- G03GA01 - Chorionic gonadotrophin
- G03GA05 - Follitropin alfa
- G03GA06 - Follitropin beta
- G03GA07 - Lutropin alfa
- G03GA09 - Corifollitropin alfa
- G03X - Other sex hormones and modulators of the genital system
- G03XB - Antiprogestogens
- G03XC - Selective estrogen receptor modulators
- G03XC01 - Raloxifene
- G03XC02 - Bazedoxifene
- G03XC03 - Lasofoxifene
- G04 - Urologicals
- G04B - Other urologicals, including antispasmodics
- G04BD - Urinary antispasmodics
- G04BD04 - Oxybutynin
- G04BD10 - Darifenacin
- G04BD11 - Fesoterodine
- G04BE - Drugs used in erectile dysfunction
- G04BE03 - Sildenafil
- G04BE07 - Apomorphine
- G04BE08 - Tadalafil
- G04BE09 - Vardenafil
- G04C - Drugs used in benign prostatic hypertrophy
- G04CA - Alpha-adrenoreceptor antagonists
- H - Systemic hormonal prep, excluding sex hormones
- H01 - Pituitary and hypothalamic hormones
- H01A - Anterior pituitary lobe hormones
- H01AB - Thyrotropin
- H01AC - Somatropin and analogues
- H01AC01 - Somatropin
- H01AC03 - Mecasermin
- H01AX - Other anterior pituitary lobe hormones and analogues
- H01C - Hypothalamic hormones
- H01CA - Gonadotrophin-releasing hormones
- H01CB - Antigrowth hormone
- H01CC - Anti-gonadotropin-releasing hormones
- H02 - Corticosteroids for systemic use
- H02A - Corticosteroids for systemic use, plain
- H02AB - Glucocorticoids
- H02AB02 - Dexamethasone
- H02AB09 - Hydrocortisone
- H05 - Calcium homeostasis
- H05A - Parathyroid hormones
- H05AA - Parathyroid hormones
- H05AA02 - Teriparatide
- H05AA03 - Parathyroid hormone
- H05B - Anti-parathyroid hormones
- H05BA - Calcitonin preparations
- H05BA01 - Calcitonin (salmon synthetic)
- H05BX - Other anti-parathyroid agents
- J - General antiinfectives for systemic use
- J01 - Antibacterials for systemic use
- J01A - Tetracyclines
- J01C - Beta-lactam antibacterials, penicillins
- J01CE - Beta-lactamase sensitive penicillins
- J01CE08 - Benzathine benzylpenicillin
- J01CR - Combinations of penicillins, including beta-lactamase inhibitors
- J01CR02 - Amoxicillin and enzyme inhibitor
- J01CR05 - Piperacillin and enzyme inhibitor
- J01D - Other beta-lactam antibacterials
- J01DD - Third-generation cephalosporins
- J01DD02 - Ceftazidime
- J01DD04 - Ceftriaxone
- J01DF - Monobactams
- J01DH - Carbapenems
- J01DH02 - Meropenem
- J01DH03 - Ertapenem
- J01DH04 - Doripenem
- J01DH51 - Imipenem and enzyme inhibitor
- J01DI - Other cephalosporins
- J01DI01 - Ceftobiprole medocaril
- J01F - Macrolides and lincosamides
- J01G - Aminoglycoside antibacterials
- J01GB - Other aminoglycosides
- J01M - Quinolone antibacterials
- J01MA - Fluoroquinolones
- J01MA02 - Ciprofloxacin
- J01MA09 - Sparfloxacin
- J01MA13 - Trovafloxacin
- J01MA14 - Moxifloxacin
- J01MA16 - Gatifloxacin
- J01X - Other antibacterials
- J01XA - Glycopeptide antibacterials
- J01XA02 - Teicoplanin
- J01XA03 - Telavancin
- J01XX - Other antibacterials
- J02 - Antimycotics for systemic use
- J02A - Antimycotics for systemic use
- J02AC - Triazole derivatives
- J02AC01 - Fluconazole
- J02AC03 - Voriconazole
- J02AC04 - Posaconazole
- J02AX - Other antimycotics for systemic use
- J02AX04 - Caspofungin
- J02AX05 - Micafungin
- J02AX06 - Anidulafungin
- J05 - Antivirals for systemic use
- J05A - Agents affecting the virus directly
- J05AB - Nucleosides
- J05AB04 - Ribavirin
- J05AB06 - Ganciclovir
- J05AB09 - Famciclovir
- J05AB11 - Valaciclovir
- J05AB12 - Cidofovir
- J05AE - Protease inhibitors
- J05AE01 - Saquinavir
- J05AE02 - Indinavir
- J05AE03 - Ritonavir
- J05AE04 - Nelfinavir
- J05AE05 - Amprenavir
- J05AE06 - Lopinavir
- J05AE07 - Fosamprenavir
- J05AE08 - Atazanavir
- J05AE09 - Tipranavir
- J05AE10 - Darunavir
- J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
- J05AF04 - Stavudine
- J05AF05 - Lamivudine
- J05AF06 - Abacavir
- J05AF07 - Tenofovir disoproxil
- J05AF08 - Adefovir dipivoxil
- J05AF09 - Emtricitabine
- J05AF10 - Entecavir
- J05AF11 - Telbivudine
- J05AG - Non-nucleoside reverse transcriptase inhibitors
- J05AG01 - Nevirapine
- J05AG03 - Efavirenz
- J05AG04 - Etravirine
- J05AG05 - Rilpivirine
- J05AH - Neuraminidase inhibitors
- J05AR - Antivirals for treatment of hiv infections, combinations
- J05AR01 - Zidovudine and lamivudine
- J05AR02 - Lamivudine and abacavir
- J05AR03 - Tenofovir disoproxil and emtricitabine
- J05AR06 - Emtricitabine, tenofovir disoproxil and efavirenz
- J05AR08 - Emtricitabine, rilpivirine and tenofovir disoproxil
- J05AX - Other antivirals
- J05AX07 - Enfuvirtide
- J05AX08 - Raltegravir
- J05AX09 - Maraviroc
- J06 - Immune sera and immunoglobulins
- J06B - Immunoglobulins
- J06BA - Immunoglobulins, normal human
- J06BA01 - Immunoglobulins, normal human, for extravascular administration
- J06BA02 - Immunoglobulins, normal human, for intravascular administration
- J06BB - Specific immunoglobulins
- J06BB04 - Hepatitis B immunoglobulin
- J06BB16 - Palivizumab
- J07 - Vaccines
- J07A - Bacterial vaccines
- J07AE - Cholera vaccines
- J07AE01 - Cholera, inactivated, whole cell
- J07AH - Meningococcal vaccines
- J07AH08 - Meningococcus, tetravalent purified polysaccharides antigen conjugated
- J07AL - Pneumococcal vaccines
- J07AL02 - Pneumococcus, purified polysaccharides antigen conjugated
- J07AL52 - Pneumococcus purified polysaccharides antigen and Haemophilus influenzae, conjugated
- J07B - Viral vaccines
- J07BA - Encephalitis vaccines
- J07BA02 - Encephalitis, japanese, inactivated, whole virus
- J07BB - Influenza vaccines
- J07BB01 - Influenza, inactivated, whole virus
- J07BB02 - Influenza, purified antigen
- J07BB03 - Influenza, live attenuated
- J07BC - Hepatitis vaccines
- J07BC01 - Hepatitis B, purified antigen
- J07BC20 - Combinations
- J07BD - Measles vaccines
- J07BD52 - Measles, combinations with mumps and rubella, live attenuated
- J07BD54 - Measles, combinations with mumps, rubella and varicella, live attenuated
- J07BH - Rota virus diarrhea vaccines
- J07BH01 - Rota virus, live attenuated
- J07BH02 - Rota virus, pentavalent, live, reassorted
- J07BK - Varicella zoster vaccines
- J07BK02 - Zoster, live attenuated
- J07BL - Yellow fever vaccines
- J07BL01 - Yellow fever, live attenuated
- J07BM - Papillomavirus vaccines
- J07BM01 - Papillomavirus (human types 6, 11, 16, 18)
Papillomavirus (human types 16, 18)
- J07BM02 - Papillomavirus (human types 16, 18)
- J07C - Bacterial and viral vaccines, combined
- J07CA - Bacterial and viral vaccines, combined
- J07CA01 - Diphtheria-poliomyelitis-tetanus
- J07CA05 - Diphtheria-hepatitis B-pertussis-tetanus
- J07CA07 - Diphtheria-hepatitis B-tetanus
- J07CA08 - Hemophilus influenzae B and hepatitis B
- J07CA09 - Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
- J07CA10 - Typhoid-hepatitis A
- J07CA12 - Diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B
- L - Antineoplastic and immunomodulating agents
- L01 - Cytostatics
- L01A - Alkylating agents
- L01AB - Alkyl sulphonates
- L01AC - Ethylene imines
- L01AX - Other alkylating agents
- L01AX03 - Temozolomide
- L01AX04 - Dacarbazine
- L01B - Antimetabolites
- L01BA - Folic acid analogues
- L01BB - Purine analogues
- L01BB02 - Mercaptopurine
- L01BB04 - Cladribine
- L01BB06 - Clofarabine
- L01BB07 - Nelarabine
- L01BC - Pyrimidine analogues
- L01BC01 - Cytarabine
- L01BC05 - Gemcitabine
- L01BC06 - Capecitabine
- L01BC07 - Azacitidine
- L01BC53 - Tegafur, combinations
- L01C - Plant alkaloids and other natural products
- L01CA - Vinca alkaloids and analogues
- L01CD - Taxanes
- L01CD01 - Paclitaxel
- L01CD02 - Docetaxel
- L01CX - Other plant alkaloids and natural products
- L01D - Cytotoxic antibiotics
- L01X - Other cytostatics
- L01XC - Monoclonal antibodies
- L01XC02 - Rituximab
- L01XC03 - Trastuzumab
- L01XC04 - Alemtuzumab
- L01XC06 - Cetuximab
- L01XC07 - Bevacizumab
- L01XC08 - Panitumumab
- L01XC09 - Catumaxomab
- L01XC10 - Ofatumumab
- L01XC11 - Ipilimumab
- L01XD - Sensitizers used in photodynamic/radiation therapy
- L01XD01 - Porfimer sodium
- L01XD04 - Aminolevulinic acid
- L01XD05 - Temoporfin
- L01XE - Protein kinase inhibitors
- L01XE01 - Imatinib
- L01XE02 - Gefitinib
- L01XE03 - Erlotinib
- L01XE04 - Sunitinib
- L01XE05 - Sorafenib
- L01XE06 - Dasatinib
- L01XE07 - Lapatinib
- L01XE08 - Nilotinib
- L01XE09 - Temsirolimus
- L01XE10 - Everolimus
- L01XE11 - Pazopanib
- L01XE12 - Vandetanib
- L01XE15 - Vemurafenib
- L01XX - Other cytostatics
- L01XX05 - Hydroxycarbamide
- L01XX17 - Topotecan
- L01XX22 - Alitretinoin
- L01XX23 - Mitotane
- L01XX25 - Bexarotene
- L01XX27 - Arsenic trioxide
- L01XX32 - Bortezomib
- L01XX33 - Celecoxib
- L01XX35 - Anagrelide
- L01XX41 - Eribulin
- L02 - Endocrine therapy
- L02B - Hormone antagonists and related agents
- L02BA - Anti-estrogens
- L02BA02 - Toremifene
- L02BA03 - Fulvestrant
- L02BB - Anti-androgens
- L02BG - Enzyme inhibitors
- L02BX - Other hormone antagonists and related agents
- L02BX02 - Degarelix
- L02BX03 - Abiraterone
- L03 - Immunomodulating agents
- L03A - Immunostimulating agents
- L03AA - Cytokines
- L03AA02 - Filgrastim
- L03AA03 - Molgramostim
- L03AA13 - Pegfilgrastim
- L03AB - Interferons
- L03AB01 - Interferon alfa natural
- L03AB05 - Interferon alfa-2b
- L03AB07 - Interferon beta-1a
- L03AB08 - Interferon beta-1b
- L03AB09 - Interferon alfacon-1
- L03AB10 - Peginterferon alfa-2b
- L03AB11 - Peginterferon alfa-2a
- L03AX - Other immunostimulating agents
- L03AX11 - Tasonermin
- L03AX14 - Histamine dihydrochloride
- L03AX15 - Mifamurtide
- L03AX16 - Plerixafor
- L04 - Immunosuppressive agents
- L04A - Immunosuppressive agents
- L04AA - Selective immunosuppressive agents
- L04AA02 - Muromonab-CD3
- L04AA06 - Mycophenolic acid
- L04AA10 - Sirolimus
- L04AA13 - Leflunomide
- L04AA21 - Efalizumab
- L04AA23 - Natalizumab
- L04AA24 - Abatacept
- L04AA25 - Eculizumab
- L04AA26 - Belimumab
- L04AA27 - Fingolimod
- L04AA28 - Belatacept
- L04AB - Tumor necrosis factor alpha (TNF-a) inhibitors
- L04AB02 - Infliximab
- L04AB04 - Adalimumab
- L04AB05 - Certolizumab pegol
- L04AB06 - Golimumab
- L04AB01 - Etanercept
- L04AB02 - Infliximab
- L04AB04 - Adalimumab
- L04AB05 - Certolizumab pegol
- L04AB06 - Golimumab
- L04AC - Interleukin inhibitors
- L04AC01 - Daclizumab
- L04AC03 - Anakinra
- L04AC04 - Rilonacept
- L04AC05 - Ustekinumab
- L04AC07 - Tocilizumab
- L04AC08 - Canakinumab
- L04AD - Calcineurin inhibitors
- L04AD02 - Tacrolimus
- L04AD03 - Voclosporin
- L04AX - Other immunosuppressive agents
- L04AX02 - Thalidomide
- L04AX04 - Lenalidomide
- L04AX05 - Pirfenidone
- M - Musculo-skeletal system
- M01 - Antiinflammatory and antirheumatic products
- M01A - Antiinflammatory and antirheumatic products, non-steroids
- M01AC - Oxicams
- M01AC01 - Piroxicam
- M01AC05 - Lornoxicam
- M01AE - Propionic acid derivatives
- M01AH - Coxibs
- M01AH02 - Rofecoxib
- M01AH03 - Valdecoxib
- M01AH04 - Parecoxib
- M01AH05 - Etoricoxib
- M01AH06 - Lumiracoxib
- M01AX - Other antiinflammatory and antirheumatic agents, non-steroids
- M01AX05 - Glucosamine
- M01AX17 - Nimesulide
- M03 - Muscle relaxants
- M03A - Muscle relaxants, peripherally acting agents
- M03AX - Other muscle relaxants, peripherally acting
- M03AX01 - Botulinum toxin
- M03B - Muscle relaxants, centrally acting agents
- M03BA - Carbamic acid esters
- M03BB - Oxazol-, thiazine-, triazine derivatives
- M03BX - Other centrally acting agents
- M04 - Antigout preparations
- M04A - Antigout preparations
- M04AA - Preparations inhibiting uric acid production
- M05 - Drugs for treatment of bone diseases
- M05B - Drugs affecting bone structure and mineralization
- M05BA - Biphosphonates
- M05BA04 - Alendronic acid
- M05BA06 - Ibandronic acid
- M05BA08 - Zoledronic acid
- M05BB - Bisphosphonates, combinations
- M05BB03 - Alendronic acid and colecalciferol
- M05BC - Bone morphogenetic proteins
- M05BC01 - Dibotermin alfa
- M05BC02 - Eptotermin alfa
- M05BX - Other drugs affecting bone structure and mineralization
- M05BX03 - Strontium ranelate
- M05BX04 - Denosumab
- M09 - Other drugs for disorders of the musculo-skeletal system
- M09A - Other drugs for disorders of the musculo-skeletal system
- M09AB - Enzymes
- M09AB02 - Collagenase clostridium histolyticum
- M09AX - Other drugs for disorders of the musculo-skeletal system
- M09AX02 - Chondrocytes, autologous
- N - Nervous system
- N01 - Anesthetics
- N01A - Anesthetics, general
- N01AH - Opioid anesthetics
- N01B - Anesthetics, local
- N01BX - Other local anesthetics
- N02 - Analgesics
- N02A - Opioids
- N02AB - Phenylpiperidine derivatives
- N02AX - Other opioids
- N02B - Other analgesics and antipyretics
- N02BG - Other analgesics and antipyretics
- N02C - Antimigraine preparations
- N02CX - Other antimigraine preparations
- N03 - Antiepileptics
- N03A - Antiepileptics
- N03AF - Carboxamide derivatives
- N03AF03 - Rufinamide
- N03AF04 - Eslicarbazepine
- N03AG - Fatty acid derivatives
- N03AX - Other antiepileptics
- N03AX09 - Lamotrigine
- N03AX11 - Topiramate
- N03AX12 - Gabapentin
- N03AX14 - Levetiracetam
- N03AX15 - Zonisamide
- N03AX16 - Pregabalin
- N03AX17 - Stiripentol
- N03AX18 - Lacosamide
- N03AX21 - Retigabine
- N04 - Anti-parkinson drugs
- N04B - Dopaminergic agents
- N04BA - Dopa and dopa derivatives
- N04BA03 - Levodopa, decarboxylase inhibitor and COMT inhibitor
- N04BC - Dopamine agonists
- N04BC04 - Ropinirole
- N04BC05 - Pramipexole
- N04BC09 - Rotigotine
- N04BD - Monoamine oxidase type B inhibitors
- N04BX - Other dopaminergic agents
- N04BX01 - Tolcapone
- N04BX02 - Entacapone
- N05 - Psycholeptics
- N05A - Antipsychotics
- N05AE - Indole derivatives
- N05AH - Diazepines, oxazepines, thiazepines and oxepines
- N05AH02 - Clozapine
- N05AH03 - Olanzapine
- N05AH04 - Quetiapine
- N05AH05 - Asenapine
- N05AL - Benzamides
- N05AX - Other antipsychotics
- N05AX08 - Risperidone
- N05AX12 - Aripiprazole
- N05AX13 - Paliperidone
- N05C - Hypnotics and sedatives
- N05CD - Benzodiazepine derivatives
- N05CF - Cyclopyrrolones
- N05CH - Melatonin receptor agonists
- N05CM - Other hypnotics and sedatives
- N05CM18 - Dexmedetomidine
- N06 - Psychoanaleptics
- N06A - Antidepressants
- N06AB - Bicyclic derivatives
- N06AB03 - Fluoxetine
- N06AB04 - Citalopram
- N06AB05 - Paroxetine
- N06AB06 - Sertraline
- N06AB08 - Fluvoxamine
- N06AB10 - Escitalopram
- N06AX - Other antidepressants
- N06AX11 - Mirtazapine
- N06AX12 - Bupropion
- N06AX16 - Venlafaxine
- N06AX17 - Milnacipran
- N06AX18 - Reboxetine
- N06AX21 - Duloxetine
- N06AX22 - Agomelatine
- N06B - Psychostimulants
- N06BA - Phenylethylamine derivatives
- N06BA04 - Methylphenidate
- N06BA09 - Atomoxetine
- N06BC - Xanthine derivatives
- N06BC01 - Caffeine
- N06BC02 - Propentofylline
- N06D - Anti-dementia drugs
- N06DA - Anticholinesterases
- N06DX - Other anti-dementia drugs
- N07 - Other nervous system drugs
- N07B - Drugs used in addictive disorders
- N07BA - Drugs used in nicotine dependence
- N07BC - Drugs used in opioid dependence
- N07BC03 - Levacetylmethadol
- N07BC51 - Buprenorphine, combinations
- N07C - Antivertigo preparations
- N07CA - Antivertigo preparations
- N07X - Other nervous system drugs
- N07XX - Other nervous system drugs
- N07XX02 - Riluzole
- N07XX04 - Hydroxybutyric acid
- N07XX05 - Amifampridine
- N07XX07 - Fampridine
- N07XX08 - Tafamidis
- P - Antiparasitic products
- P01 - Antiprotozoals
- P01B - Antimalarials
- P01BF - Artemisinin and derivatives, combinations
- P01BF05 - Artenimol and piperaquine
- R - Respiratory system
- R01 - Nasal preparations
- R01A - Nasal decongestants for topical use
- R01AD - Corticosteroids
- R01AD12 - Flucticasone furoate
- R03 - Anti-asthmatics
- R03A - Adrenergics, inhalants
- R03AC - Selective beta-2-adrenoceptor agonists
- R03AC02 - Salbutamol
- R03AC13 - Formoterol
- R03AC18 - Indacaterol
- R03AK - Adrenergics and other anti-asthmatics
- R03AK06 - Salmeterol and other drugs for obstructive airway diseases
- R03B - Other anti-asthmatics, inhalants
- R03BA - Glucocorticoids
- R03BA02 - Budesonide
- R03BA08 - Ciclesonide
- R03D - Other anti-asthmatics for systemic use
- R03DC - Leukotriene receptor antagonists
- R03DX - Other anti-asthmatics for systemic use
- R03DX05 - Omalizumab
- R03DX07 - Roflumilast
- R05 - Cough and cold preparations
- R05C - Expectorants, excluding combinations with antitussives
- R05D - Antitussives, excluding combinations with expectorants
- R05DA - Opium alkaloids and derivatives
- R05DB - Antitussives chemically close to local anesthetics
- R06 - Antihistamines for systemic use
- R06A - Antihistamines for systemic use
- R06AE - Piperazine derivatives
- R06AX - Other antihistamines for systemic use
- R06AX12 - Terfenadine
- R06AX13 - Loratadine
- R06AX25 - Mizolastine
- R06AX27 - Desloratadine
- R07 - Other respiratory system products
- R07A - Other respiratory system products
- R07AX - Other respiratory system products
- S - Sensory organs
- S01 - Ophthalmologicals
- S01A - Antiinfectives
- S01AD - Antivirals
- S01AX - Other antiinfectives
- S01B - Antiinflammatory agents
- S01BA - Corticosteroids, plain
- S01BC - Antiinflammatory agents, non-steroids
- S01BC10 - Nepafenac
- S01BC11 - Bromfenac
- S01E - Antiglaucoma preparations and miotics
- S01EC - Carbonic anhydrase inhibitors
- S01ED - Beta blocking agents
- S01ED51 - Timolol, combinations
- S01EE - Prostaglandin analogues
- S01EE01 - Latanoprost
- S01EE03 - Bimatoprost
- S01EE04 - Travoprost
- S01G - Decongestants and antiallergics
- S01GX - Other antiallergics
- S01GX06 - Emedastine
- S01GX09 - Olopatadine
- S01L - Ocular vascular disorder agents
- S01LA - Antineovascularisation agents
- S01LA01 - Verteporfin
- S01LA03 - Pegaptanib
- S01LA04 - Ranibizumab
- V - Various
- V03 - All other therapeutic products
- V03A - All other therapeutic products
- V03AB - Antidotes
- V03AB17 - Methylthionine
- V03AB33 - Hydroxocobalamin
- V03AB35 - Sugammadex
- V03AC - Iron chelating agents
- V03AC02 - Deferiprone
- V03AC03 - Deferasirox
- V03AE - Drugs for treatment of hyperkalemia and hyperphosphatemia
- V03AF - Detoxifying agents for antineoplastic treatment
- V03AF02 - Dexrazoxane
- V03AF03 - Calcium folinate
- V03AF07 - Rasburicase
- V03AF08 - Palifermin
- V03AX - Other therapeutic products
- V04 - Diagnostic agents
- V04C - Other diagnostic agents
- V04CX - Other diagnostic agents
- V08 - Contrast media
- V08C - Magnetic resonance imaging contrast media
- V08CA - Paramagnetic contrast media
- V08CA02 - Gadoteric acid
- V08CA05 - Mangafodipir
- V08CA06 - Gadoversetamide
- V08CA08 - Gadobenic acid
- V08CA09 - Gadobutrol
- V08CA11 - Gadofosveset
- V08D - Ultrasound contrast media
- V08DA - Ultrasound contrast media
- V08DA01 - Microspheres of human albumin
- V08DA04 - Microspheres of phospholipids
- V08DA05 - Sulfur hexafluoride
- V09 - Diagnostic radiopharmaceuticals
- V09A - Central nervous system
- V09AB - Iodine (123I) compounds
- V09AB03 - Iodine ioflupane (123I)
- V09H - Inflammation and infection detection
- V09HA - Technetium (99mTc) compounds
- V09HA03 - Technetium (99mTc) antigranulocyte antibody
- V09HA04 - Technetium (99mTc) sulesomab
- V09I - Tumour detection
- V09IA - Technetium (99mTc) compounds
- V09IA01 - Technetium (99mTc) antiCarcinoEmbryonicAntigen antibody
- V09IA02 - Technetium (99mTc) antimelanoma antibody
- V09IA05 - Technetium (99mTc) depreotide
- V09IB - Indium (111In) compounds
- V09IB03 - Indium (111In) antiovariumcarcinoma antibody
- V09IX - Other diagnostic radiopharmaceuticals for tumour detection
- V09IX04 - Fludeoxyglucose (18F)
- V10 - Therapeutic radiopharmaceuticals
- V10B - Pain palliation (bone seeking agents)
- V10BX - Various pain palliation radiopharmaceuticals
- V10BX02 - Samarium (153Sm) lexidronam
- V10X - Other therapeutic radiopharmaceuticals
- V10XX - Various therapeutic radiopharmaceuticals
- V10XX02 - Ibritumomab tiuxetan
|
